Lasmiditan

Rayvow 50 MG Comprimidos Recubiertos con Pelicula

57,824 mg comprimido recubierto con películaSpainAuthorisedAuthorised 16 Sept 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

RayvowEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Lasmiditan

Rayvow 50 MG Comprimidos Recubiertos con Pelicula

57,824 mg comprimido recubierto con películaSpainAuthorisedAuthorised 16 Sept 2022

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

RayvowEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Netherlands · Filmomhulde tablet · Eli Lilly Nederland B.V.

ReyvowUnited States · 100MG BASE, 200MG BASE, 50MG BASE · tablet · Eli Lilly and Co

LasmiditanUnited States · 100MG, 50MG · tablet · Qilu Pharmaceutical Co., LTD.

ReyvowSaudi Arabia · Lilly del Caribe, INC.

Packs

Pack	Code	Status
RAYVOW 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 2 comprimidos	758199
RAYVOW 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULA, 6 comprimidos	758200

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lasmiditan
Strength: 57,824 mg
Dosage form: comprimido recubierto con película
Route: vía oral
Register: Spain (AEMPS)
Status: Authorised
Status in the register: Autorizado, no comercializado
Authorised: 16 Sept 2022
Registration: 1211587006
Marketing authorisation holder: Eli Lilly Nederland B.V.
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica
EU number: EU/1/21/1587